J&J Rides Consumer Health ‘Growth Annuity’ As Rx, Device Divisions Slow

Johnson & Johnson’s second-quarter U.S. OTC sales jumped nearly 16% on the return of recalled brands and Worldwide Group Chairman Peterson says J&J expects the consumer business to grow “increasingly” more robust.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia